董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Natalie Holles | 女 | Lead Independent Director | 49 | 未披露 | 未持股 | 2021-05-26 |
| Dan Becker | 男 | Director | 45 | 未披露 | 未持股 | 2021-05-26 |
| Julie Grant | 女 | Chair of the Board, Director and Co-Founder | 38 | 4.72万美元 | 未持股 | 2021-05-26 |
| Michael Gladstone | 男 | Director | 34 | 未披露 | 未持股 | 2021-05-26 |
| John Josey | 男 | Director | 60 | 11.84万美元 | 未持股 | 2021-05-26 |
| Jeremy Bender | 男 | Chief Executive Officer, President and Director | 49 | 275.32万美元 | 未持股 | 2021-05-26 |
| Dan Becker | 男 | Director | 45 | 未披露 | 未持股 | 2021-05-26 |
| Saira Ramasastry | 女 | Director | 45 | 未披露 | 未持股 | 2021-05-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Julie Grant | 女 | Chair of the Board, Director and Co-Founder | 38 | 4.72万美元 | 未持股 | 2021-05-26 |
| Jeremy Bender | 男 | Chief Executive Officer, President and Director | 49 | 275.32万美元 | 未持股 | 2021-05-26 |
| Charles York II | 男 | Chief Operating Officer, Chief Financial Officer and Secretary | 44 | 未披露 | 未持股 | 2021-05-26 |
| Samuel Blackman | 男 | Chief Medical Officer and Co-Founder | 52 | 47.71万美元 | 未持股 | 2021-05-26 |
董事简历
中英对照 | 中文 | 英文- Natalie Holles
-
Natalie Holles，自2015年8月起担任高级副总裁兼首席运营官；2013年6月至2015年5月Hyperion Therapeutics, Inc.（罕见遗传病制药公司）被Horizon Pharma, plc收购前担任前者的企业发展高级副总裁；2012年8月至2013年6月间担任Immune Design, Inc.（免疫疗法公司）的企业发展执行副总裁；2010年12月至2013年6月间是一名独立生命科学企业发展顾问；早期担任KAI Pharmaceuticals, Inc.的业务开发副总裁，此前担任InterMune, Inc.和Genentech, Inc.的企业发展和商业化方面职位。她获得了Stanford University的学士学位，和博尔德the University of Colorado的硕士学位。
Natalie Holles has served as Third Harmonic Bio, Inc. Chief Executive Officer and a member of Third Harmonic Bio, Inc. board of directors since August 2021. Prior to joining Third Harmonic Bio, Inc., Ms. Holles worked at Audentes Therapeutics, Inc., or Audentes, serving as President and Chief Executive Officer from January 2020 through March 2021 President and Chief Operating Officer from May 2018 to January 2020 and Senior Vice President, Chief Operating Officer from August 2015 to May 2018. Previously, Ms. Holles served as Senior Vice President, Corporate and Business Development at Hyperion Therapeutics, Inc., from June 2013 through its acquisition by Horizon Pharma, plc in May 2015. From December 2010 to June 2013 Ms. Holles served as an independent life sciences corporate development consultant. Earlier in her career, Ms. Holles served as the Vice President, Business Development at KAI Pharmaceuticals, Inc., which was acquired by Amgen, Inc. in 2012 and previously held business development and commercial roles at InterMune, Inc. and Genentech, Inc. In addition to serving on Third Harmonic Bio, Inc. board of directors, Ms. Holles also currently serves on the board of Day One Biopharmaceuticals, Inc. since January 2021. Formerly, Ms. Holles served on the board of directors of Rubius Therapeutics, Inc. from March 2019 to August 2022 and Allakos Inc. from December 2020 to August 2021. Ms. Holles holds a B.A. in human biology from Stanford University and an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder. - Natalie Holles，自2015年8月起担任高级副总裁兼首席运营官；2013年6月至2015年5月Hyperion Therapeutics, Inc.（罕见遗传病制药公司）被Horizon Pharma, plc收购前担任前者的企业发展高级副总裁；2012年8月至2013年6月间担任Immune Design, Inc.（免疫疗法公司）的企业发展执行副总裁；2010年12月至2013年6月间是一名独立生命科学企业发展顾问；早期担任KAI Pharmaceuticals, Inc.的业务开发副总裁，此前担任InterMune, Inc.和Genentech, Inc.的企业发展和商业化方面职位。她获得了Stanford University的学士学位，和博尔德the University of Colorado的硕士学位。
- Natalie Holles has served as Third Harmonic Bio, Inc. Chief Executive Officer and a member of Third Harmonic Bio, Inc. board of directors since August 2021. Prior to joining Third Harmonic Bio, Inc., Ms. Holles worked at Audentes Therapeutics, Inc., or Audentes, serving as President and Chief Executive Officer from January 2020 through March 2021 President and Chief Operating Officer from May 2018 to January 2020 and Senior Vice President, Chief Operating Officer from August 2015 to May 2018. Previously, Ms. Holles served as Senior Vice President, Corporate and Business Development at Hyperion Therapeutics, Inc., from June 2013 through its acquisition by Horizon Pharma, plc in May 2015. From December 2010 to June 2013 Ms. Holles served as an independent life sciences corporate development consultant. Earlier in her career, Ms. Holles served as the Vice President, Business Development at KAI Pharmaceuticals, Inc., which was acquired by Amgen, Inc. in 2012 and previously held business development and commercial roles at InterMune, Inc. and Genentech, Inc. In addition to serving on Third Harmonic Bio, Inc. board of directors, Ms. Holles also currently serves on the board of Day One Biopharmaceuticals, Inc. since January 2021. Formerly, Ms. Holles served on the board of directors of Rubius Therapeutics, Inc. from March 2019 to August 2022 and Allakos Inc. from December 2020 to August 2021. Ms. Holles holds a B.A. in human biology from Stanford University and an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder.
- Dan Becker
-
Dan Becker自2017年以来一直担任我们的董事会成员。Becker博士是New Leaf Venture Partners的负责人，于2015年加入该公司。从2009年到2015年，他曾担任The Boston Consulting Group（管理咨询公司）的负责人，在那里他曾担任他们的医疗实践的核心成员，并领导医疗保健部门的项目，专注于生物制药研发。Becker从2006年到2009年在Brigham and Women&8217；s Hospital和Massachusetts General Hospital接受内科和肾脏学临床培训，是Harvard Medical School研究员。他在密歇根大学（University of Michigan）获得细胞和分子生物学硕士学位和博士学位，并在伊利诺伊大学香槟分校（University of Illinois at Urbana-Champaign）获得生理学学士学位。
Dan Becker has served as a member of our board of directors since December 2019. He is a Partner at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, a privately held US-based industrial group, since August 2019. Prior to joining Access, Dr. Becker was a Principal at New Leaf Venture Partners, a venture capital firm, from January 2015 to May 2019 and a Principal in the Health Care practice at the Boston Consulting Group, from August 2009 to January 2015. Dr. Becker trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. He obtained both his M.D. and Ph.D. Cellular and Molecular Biology degrees from the University of Michigan, and received his B.S. in Physiology from the University of Illinois at Urbana-Champaign. - Dan Becker自2017年以来一直担任我们的董事会成员。Becker博士是New Leaf Venture Partners的负责人，于2015年加入该公司。从2009年到2015年，他曾担任The Boston Consulting Group（管理咨询公司）的负责人，在那里他曾担任他们的医疗实践的核心成员，并领导医疗保健部门的项目，专注于生物制药研发。Becker从2006年到2009年在Brigham and Women&8217；s Hospital和Massachusetts General Hospital接受内科和肾脏学临床培训，是Harvard Medical School研究员。他在密歇根大学（University of Michigan）获得细胞和分子生物学硕士学位和博士学位，并在伊利诺伊大学香槟分校（University of Illinois at Urbana-Champaign）获得生理学学士学位。
- Dan Becker has served as a member of our board of directors since December 2019. He is a Partner at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, a privately held US-based industrial group, since August 2019. Prior to joining Access, Dr. Becker was a Principal at New Leaf Venture Partners, a venture capital firm, from January 2015 to May 2019 and a Principal in the Health Care practice at the Boston Consulting Group, from August 2009 to January 2015. Dr. Becker trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. He obtained both his M.D. and Ph.D. Cellular and Molecular Biology degrees from the University of Michigan, and received his B.S. in Physiology from the University of Illinois at Urbana-Champaign.
- Julie Grant
-
朱莉·格兰特（Julie Grant）从2018年11月至2020年9月1日是我们的联合创始人兼前首席执行官，自2018年11月以来一直担任我们的董事会成员。Grant女士目前是Canaan的普通合伙人，并于2013年7月加入合伙企业。在加入Canaan之前，Grant女士在制药公司Genentech担任过各种开发和商业职务。格兰特女士还担任各种私人生命科学公司的董事会成员。Grant女士获得了斯坦福商学院的工商管理硕士学位，剑桥大学的生物科学企业硕士学位以及耶鲁大学的分子生物物理和生物化学学士学位。
Julie Grant is our co-founder and our former Chief Executive Officer from November 2018 to September 1 2020 and has served as a member of our board of directors since November 2018. Ms. Grant is currently a General Partner at Canaan and joined the partnership in July 2013. Prior to Canaan, Ms. Grant served in a variety of development and commercial roles at Genentech, a pharmaceutical company. Ms. Grant also sits on various private life sciences company boards. Ms. Grant received an M.B.A. from the Stanford Graduate School of Business, an MPhil in BioScience Enterprise from Cambridge University, and a B.S. in Molecular Biophysics and Biochemistry from Yale University. - 朱莉·格兰特（Julie Grant）从2018年11月至2020年9月1日是我们的联合创始人兼前首席执行官，自2018年11月以来一直担任我们的董事会成员。Grant女士目前是Canaan的普通合伙人，并于2013年7月加入合伙企业。在加入Canaan之前，Grant女士在制药公司Genentech担任过各种开发和商业职务。格兰特女士还担任各种私人生命科学公司的董事会成员。Grant女士获得了斯坦福商学院的工商管理硕士学位，剑桥大学的生物科学企业硕士学位以及耶鲁大学的分子生物物理和生物化学学士学位。
- Julie Grant is our co-founder and our former Chief Executive Officer from November 2018 to September 1 2020 and has served as a member of our board of directors since November 2018. Ms. Grant is currently a General Partner at Canaan and joined the partnership in July 2013. Prior to Canaan, Ms. Grant served in a variety of development and commercial roles at Genentech, a pharmaceutical company. Ms. Grant also sits on various private life sciences company boards. Ms. Grant received an M.B.A. from the Stanford Graduate School of Business, an MPhil in BioScience Enterprise from Cambridge University, and a B.S. in Molecular Biophysics and Biochemistry from Yale University.
- Michael Gladstone
-
Michael Gladstone自2019年12月以来一直担任我们的董事会成员。自2020年6月以来，他一直担任风险投资公司Atlas Venture的合伙人，此前曾于2015年5月至2020年6月担任负责人。在2012年加入Atlas之前，Gladstone先生在管理咨询公司L.E.K.Consulting工作，此前，他在Beth Israel Deaconess Medical Center的病毒致病部进行了HIV疫苗研究。迈克尔担任多个组织的顾问，包括国家Tay Sachs和Allied Diseases公司咨询委员会的成员，该公司是一个全国性组织，致力于资助研究，提高认识并支持受Tay Sachs和相关遗传病影响的家庭。Gladstone先生拥有哈佛大学生物化学学士学位。
Michael Gladstone has served as a member of Third Harmonic Bio, Inc. board of directors since April 2019. Mr. Gladstone previously served as Third Harmonic Bio, Inc. Chief Executive Officer from June 2019 through August 2021. He is a partner at Atlas Venture. Prior to joining Atlas in March 2012 Mr. Gladstone worked at L.E.K. Consulting from December 2009 through March 2012 and previously, he conducted HIV vaccine research in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center. Mr. Gladstone is a member of the Corporate Advisory Committee for National Tay Sachs and Allied Diseases and serves as an advisor to several other organizations. Since December 2019 Mr. Gladstone has served as a member of the board of directors of Day One Biopharmaceuticals, Inc. Gladstone holds an B.S. in biochemical sciences from Harvard University. - Michael Gladstone自2019年12月以来一直担任我们的董事会成员。自2020年6月以来，他一直担任风险投资公司Atlas Venture的合伙人，此前曾于2015年5月至2020年6月担任负责人。在2012年加入Atlas之前，Gladstone先生在管理咨询公司L.E.K.Consulting工作，此前，他在Beth Israel Deaconess Medical Center的病毒致病部进行了HIV疫苗研究。迈克尔担任多个组织的顾问，包括国家Tay Sachs和Allied Diseases公司咨询委员会的成员，该公司是一个全国性组织，致力于资助研究，提高认识并支持受Tay Sachs和相关遗传病影响的家庭。Gladstone先生拥有哈佛大学生物化学学士学位。
- Michael Gladstone has served as a member of Third Harmonic Bio, Inc. board of directors since April 2019. Mr. Gladstone previously served as Third Harmonic Bio, Inc. Chief Executive Officer from June 2019 through August 2021. He is a partner at Atlas Venture. Prior to joining Atlas in March 2012 Mr. Gladstone worked at L.E.K. Consulting from December 2009 through March 2012 and previously, he conducted HIV vaccine research in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center. Mr. Gladstone is a member of the Corporate Advisory Committee for National Tay Sachs and Allied Diseases and serves as an advisor to several other organizations. Since December 2019 Mr. Gladstone has served as a member of the board of directors of Day One Biopharmaceuticals, Inc. Gladstone holds an B.S. in biochemical sciences from Harvard University.
- John Josey
-
自2020年9月以来，John Josey一直担任我们的董事会成员。他曾于2013年8月至2019年7月担任PelotonTherapeutics，Inc.的总裁兼首席执行官，在此之前曾担任其总裁兼首席科学官。此前，Josey博士从2004年到2011年担任发现化学（Discovery Chemistry）的副总裁，从2000年到2004年担任Lead Generation的高级总监，从1998年到2000年担任Array BiopharmaInc.（一家生物技术公司）的高速合成高级总监。在加入Array之前，从1995年到1998年，Josey博士受雇于安进公司，这是一家生物制药公司，在安进公司’；s小分子药物发现计划的新线索/组合口服化学组工作。从1991年到1995年，Josey博士受雇于葛兰素研究所的药物化学部。自2018年6月以来，他一直担任德克萨斯大学西南医学中心生物化学系的兼职教师。Josey博士拥有科罗拉多州立大学的化学学士学位，科罗拉多大学的工商管理硕士学位和德克萨斯大学奥斯汀分校的有机化学博士学位。他也是加州理工学院的Damon Runyon-Walter Winchell博士后研究员。
John Josey has served as a member of our board of directors since September 2020. He previously served as President and Chief Executive Officer of Peloton Therapeutics, Inc., from August 2013 to July 2019 and prior to that was its President and Chief Scientific Officer. Previously, Dr. Josey was Vice President of Discovery Chemistry from 2004 to 2011 Senior Director of Lead Generation from 2000 to 2004 and Senior Director of High-Speed Synthesis from 1998 to 2000 at Array BioPharma Inc., a biotechnology company. Prior to joining Array, Dr. Josey was employed by Amgen Inc., a biopharmaceutical company, from 1995 to 1998 in the New Leads/Combinatoral Chemistry Group of Amgen Inc.’s small molecule drug discovery program. From 1991 until 1995 Dr. Josey was employed in the Medicinal Chemistry Department of Glaxo Research Institute. He has served as an adjunct faculty member of the Department of Biochemistry at University of Texas Southwestern Medical Center since June 2018. Dr. Josey received a B.S. in Chemistry from Colorado State University, an M.B.A. from the University of Colorado and a Ph.D. in Organic Chemistry from the University of Texas at Austin. He was also a Damon Runyon-Walter Winchell postdoctoral fellow at the California Institute of Technology. - 自2020年9月以来，John Josey一直担任我们的董事会成员。他曾于2013年8月至2019年7月担任PelotonTherapeutics，Inc.的总裁兼首席执行官，在此之前曾担任其总裁兼首席科学官。此前，Josey博士从2004年到2011年担任发现化学（Discovery Chemistry）的副总裁，从2000年到2004年担任Lead Generation的高级总监，从1998年到2000年担任Array BiopharmaInc.（一家生物技术公司）的高速合成高级总监。在加入Array之前，从1995年到1998年，Josey博士受雇于安进公司，这是一家生物制药公司，在安进公司’；s小分子药物发现计划的新线索/组合口服化学组工作。从1991年到1995年，Josey博士受雇于葛兰素研究所的药物化学部。自2018年6月以来，他一直担任德克萨斯大学西南医学中心生物化学系的兼职教师。Josey博士拥有科罗拉多州立大学的化学学士学位，科罗拉多大学的工商管理硕士学位和德克萨斯大学奥斯汀分校的有机化学博士学位。他也是加州理工学院的Damon Runyon-Walter Winchell博士后研究员。
- John Josey has served as a member of our board of directors since September 2020. He previously served as President and Chief Executive Officer of Peloton Therapeutics, Inc., from August 2013 to July 2019 and prior to that was its President and Chief Scientific Officer. Previously, Dr. Josey was Vice President of Discovery Chemistry from 2004 to 2011 Senior Director of Lead Generation from 2000 to 2004 and Senior Director of High-Speed Synthesis from 1998 to 2000 at Array BioPharma Inc., a biotechnology company. Prior to joining Array, Dr. Josey was employed by Amgen Inc., a biopharmaceutical company, from 1995 to 1998 in the New Leads/Combinatoral Chemistry Group of Amgen Inc.’s small molecule drug discovery program. From 1991 until 1995 Dr. Josey was employed in the Medicinal Chemistry Department of Glaxo Research Institute. He has served as an adjunct faculty member of the Department of Biochemistry at University of Texas Southwestern Medical Center since June 2018. Dr. Josey received a B.S. in Chemistry from Colorado State University, an M.B.A. from the University of Colorado and a Ph.D. in Organic Chemistry from the University of Texas at Austin. He was also a Damon Runyon-Walter Winchell postdoctoral fellow at the California Institute of Technology.
- Jeremy Bender
-
Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。
Jeremy Bender has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management. - Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。
- Jeremy Bender has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.
- Dan Becker
-
Dan Becker，自2022年9月起担任Acelyrin公司董事会成员。他目前担任Access Biotechnology的董事总经理，该公司是总部位于美国的私有工业集团Access Industries的生物制药投资部门，自2019年8月起担任董事。此前，贝克尔曾于2015年1月至2019年5月担任风险投资公司New Leaf Venture Partners的负责人，并于2009年8月至2015年1月担任波士顿咨询集团医疗保健业务的负责人。Becker博士曾在布莱根妇女医院和马萨诸塞州总医院接受内科和肾脏科的临床培训，并且是哈佛医学院的研究员。自2019年12月以来，Becker博士一直担任Day One Biopharmaceuticals, Inc.的董事会成员。此前，Becker博士曾于2017年1月至2020年9月担任上市公司Principia Biopharma Inc.的董事会成员，并于2020年3月至2021年3月担任Pandion Therapeutics公司的董事会成员。他在密歇根大学获得医学博士学位（细胞和分子生物学），并在伊利诺伊大学厄巴纳-香槟分校获得生理学学士学位。
Dan Becker,has served as a member of Acelyrin, Inc board of directors since September 2022. He currently serves as a Managing Director at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, a privately held US-based industrial group, since August 2019. Previously, Dr. Becker served as a Principal at New Leaf Venture Partners, a venture capital firm, from January 2015 to May 2019, and a Principal in the Health Care practice at the Boston Consulting Group, from August 2009 to January 2015. Dr. Becker trained clinically in internal medicine and nephrology at Brigham and Women's Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. Since December 2019, Dr. Becker has served on the board of directors of Day One Biopharmaceuticals, Inc. Previously, Dr. Becker served on the boards of directors of Principia Biopharma Inc., a publicly traded company, from January 2017 to September 2020 and Pandion Therapeutics, Inc. from March 2020 to March 2021. He obtained both his M.D. and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan, and received his B.S. in Physiology from the University of Illinois at Urbana-Champaign. - Dan Becker，自2022年9月起担任Acelyrin公司董事会成员。他目前担任Access Biotechnology的董事总经理，该公司是总部位于美国的私有工业集团Access Industries的生物制药投资部门，自2019年8月起担任董事。此前，贝克尔曾于2015年1月至2019年5月担任风险投资公司New Leaf Venture Partners的负责人，并于2009年8月至2015年1月担任波士顿咨询集团医疗保健业务的负责人。Becker博士曾在布莱根妇女医院和马萨诸塞州总医院接受内科和肾脏科的临床培训，并且是哈佛医学院的研究员。自2019年12月以来，Becker博士一直担任Day One Biopharmaceuticals, Inc.的董事会成员。此前，Becker博士曾于2017年1月至2020年9月担任上市公司Principia Biopharma Inc.的董事会成员，并于2020年3月至2021年3月担任Pandion Therapeutics公司的董事会成员。他在密歇根大学获得医学博士学位（细胞和分子生物学），并在伊利诺伊大学厄巴纳-香槟分校获得生理学学士学位。
- Dan Becker,has served as a member of Acelyrin, Inc board of directors since September 2022. He currently serves as a Managing Director at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, a privately held US-based industrial group, since August 2019. Previously, Dr. Becker served as a Principal at New Leaf Venture Partners, a venture capital firm, from January 2015 to May 2019, and a Principal in the Health Care practice at the Boston Consulting Group, from August 2009 to January 2015. Dr. Becker trained clinically in internal medicine and nephrology at Brigham and Women's Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. Since December 2019, Dr. Becker has served on the board of directors of Day One Biopharmaceuticals, Inc. Previously, Dr. Becker served on the boards of directors of Principia Biopharma Inc., a publicly traded company, from January 2017 to September 2020 and Pandion Therapeutics, Inc. from March 2020 to March 2021. He obtained both his M.D. and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan, and received his B.S. in Physiology from the University of Illinois at Urbana-Champaign.
- Saira Ramasastry
-
Saira Ramasastry，2013年2月起担任董事。2013年之前，她是本公司的顾问。她从2009年起，担任Life Sciences Advisory, LLC的管理合伙人，这是一个生命科学行业的咨询公司。1999-2009，她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998，她是投资银行公司Wasserstein Perella & Co。并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事，是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员，也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位，并在 University of Cambridge获得管理研究的学术硕士学位。
Saira Ramasastry has served as a member of our Board of Directors since March 2021. Ms. Ramasastry is the Managing Partner of Life Sciences Advisory, LLC, since April 2009 a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. From August 1999 to March 2009 Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry has served on the boards of directors of Therapeutics Inc., since June 2012 Vir Biotechnology, Inc., since September 2019 Glenmark Pharmaceuticals, Ltd., since April 2019 and Akounos, Inc. since June 2020. Ms. Ramasastry previously served on the boards of directors of Cassava Sciences, Inc., from February 2013 to June 2020 Repros Therapeutics Inc. from March 2013 until it was acquired by Allergan plc in January 2018 and Innovate Biopharmaceuticals, Inc. from June 2018 until it was acquired by RDD Pharma Ltd. in April 2020. Ms. Ramasastry received her B.A. in Economics with honors and distinction and an M.S. in Management Science and Engineering from Stanford University, as well as an M.Phil. in Management Studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. - Saira Ramasastry，2013年2月起担任董事。2013年之前，她是本公司的顾问。她从2009年起，担任Life Sciences Advisory, LLC的管理合伙人，这是一个生命科学行业的咨询公司。1999-2009，她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998，她是投资银行公司Wasserstein Perella & Co。并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事，是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员，也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位，并在 University of Cambridge获得管理研究的学术硕士学位。
- Saira Ramasastry has served as a member of our Board of Directors since March 2021. Ms. Ramasastry is the Managing Partner of Life Sciences Advisory, LLC, since April 2009 a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. From August 1999 to March 2009 Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry has served on the boards of directors of Therapeutics Inc., since June 2012 Vir Biotechnology, Inc., since September 2019 Glenmark Pharmaceuticals, Ltd., since April 2019 and Akounos, Inc. since June 2020. Ms. Ramasastry previously served on the boards of directors of Cassava Sciences, Inc., from February 2013 to June 2020 Repros Therapeutics Inc. from March 2013 until it was acquired by Allergan plc in January 2018 and Innovate Biopharmaceuticals, Inc. from June 2018 until it was acquired by RDD Pharma Ltd. in April 2020. Ms. Ramasastry received her B.A. in Economics with honors and distinction and an M.S. in Management Science and Engineering from Stanford University, as well as an M.Phil. in Management Studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.
高管简历
中英对照 | 中文 | 英文- Julie Grant
朱莉·格兰特（Julie Grant）从2018年11月至2020年9月1日是我们的联合创始人兼前首席执行官，自2018年11月以来一直担任我们的董事会成员。Grant女士目前是Canaan的普通合伙人，并于2013年7月加入合伙企业。在加入Canaan之前，Grant女士在制药公司Genentech担任过各种开发和商业职务。格兰特女士还担任各种私人生命科学公司的董事会成员。Grant女士获得了斯坦福商学院的工商管理硕士学位，剑桥大学的生物科学企业硕士学位以及耶鲁大学的分子生物物理和生物化学学士学位。
Julie Grant is our co-founder and our former Chief Executive Officer from November 2018 to September 1 2020 and has served as a member of our board of directors since November 2018. Ms. Grant is currently a General Partner at Canaan and joined the partnership in July 2013. Prior to Canaan, Ms. Grant served in a variety of development and commercial roles at Genentech, a pharmaceutical company. Ms. Grant also sits on various private life sciences company boards. Ms. Grant received an M.B.A. from the Stanford Graduate School of Business, an MPhil in BioScience Enterprise from Cambridge University, and a B.S. in Molecular Biophysics and Biochemistry from Yale University.- 朱莉·格兰特（Julie Grant）从2018年11月至2020年9月1日是我们的联合创始人兼前首席执行官，自2018年11月以来一直担任我们的董事会成员。Grant女士目前是Canaan的普通合伙人，并于2013年7月加入合伙企业。在加入Canaan之前，Grant女士在制药公司Genentech担任过各种开发和商业职务。格兰特女士还担任各种私人生命科学公司的董事会成员。Grant女士获得了斯坦福商学院的工商管理硕士学位，剑桥大学的生物科学企业硕士学位以及耶鲁大学的分子生物物理和生物化学学士学位。
- Julie Grant is our co-founder and our former Chief Executive Officer from November 2018 to September 1 2020 and has served as a member of our board of directors since November 2018. Ms. Grant is currently a General Partner at Canaan and joined the partnership in July 2013. Prior to Canaan, Ms. Grant served in a variety of development and commercial roles at Genentech, a pharmaceutical company. Ms. Grant also sits on various private life sciences company boards. Ms. Grant received an M.B.A. from the Stanford Graduate School of Business, an MPhil in BioScience Enterprise from Cambridge University, and a B.S. in Molecular Biophysics and Biochemistry from Yale University.
- Jeremy Bender
Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。
Jeremy Bender has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.- Jeremy Bender自2020年9月起担任我们的首席执行官，总裁兼董事会成员。在加入Day One之前，Bender博士于2018年3月至2020年9月担任制药公司Gilead Sciences的公司发展副总裁。在此之前，他于2015年7月至2018年3月担任Tizona Therapeutics的首席运营官，并于2012年10月至2015年7月担任专门从事癌症和自身免疫疗法的生物技术公司Sutro Biopharma的首席商务官。加入Sutro Biopharma公司之前，他曾担任Allos Therapeutics公司（生物技术公司，专注于癌症治疗）的公司发展副总裁（从2006年1月到2012年9月）。Bender博士的职业生涯始于波士顿咨询集团（Boston Consulting Group），这是一家管理咨询公司。Bender博士还是Mereo Biopharma董事会的独立董事。Bender博士拥有斯坦福大学生物科学学士学位，科罗拉多大学微生物学和免疫学博士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。
- Jeremy Bender has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.
- Charles York II
Charles York II自2021年2月起担任公司首席运营官和首席财务官。加入Day One之前，他曾担任Aeglea生物制药公司公司（生物技术公司，专注于罕见代谢疾病）的首席财务官兼副总裁，在那里他曾领导投资者关系、企业发展、通信、财务规划、会计，2014年7月加入Aeglea担任财务副总裁后，自2015年9月起担任人力资源和信息技术。在加入Aeglea之前，York先生在生命科学，制药和技术行业担任财务管理职务，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）开始其职业生涯。York先生是亚利桑那州的注册会计师，并获得了康涅狄格大学的会计学学士学位和德克萨斯大学奥斯汀分校McCombs商学院的工商管理硕士学位。
Charles York II has served as our Chief Operating Officer and Chief Financial Officer since February 2021. Immediately prior to joining Day One, Mr. York served as Chief Financial Officer and Vice President of Aeglea Biotherapeutics, Inc., a biotechnology company specializing in rare metabolic disease where he led the investor relations, corporate development, communications, financial planning, accounting, human resources and information technology since September 2015 after joining Aeglea as Vice President, Finance, in July 2014. Prior to joining Aeglea, Mr. York held financial management roles in the life science, pharmaceutical and technology industries and began his career at PricewaterhouseCoopers LLP. Mr. York is a CPA in the state of Arizona and received a B.S. in Accounting from the University of Connecticut and an MBA from the McCombs School of Business at the University of Texas at Austin.- Charles York II自2021年2月起担任公司首席运营官和首席财务官。加入Day One之前，他曾担任Aeglea生物制药公司公司（生物技术公司，专注于罕见代谢疾病）的首席财务官兼副总裁，在那里他曾领导投资者关系、企业发展、通信、财务规划、会计，2014年7月加入Aeglea担任财务副总裁后，自2015年9月起担任人力资源和信息技术。在加入Aeglea之前，York先生在生命科学，制药和技术行业担任财务管理职务，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）开始其职业生涯。York先生是亚利桑那州的注册会计师，并获得了康涅狄格大学的会计学学士学位和德克萨斯大学奥斯汀分校McCombs商学院的工商管理硕士学位。
- Charles York II has served as our Chief Operating Officer and Chief Financial Officer since February 2021. Immediately prior to joining Day One, Mr. York served as Chief Financial Officer and Vice President of Aeglea Biotherapeutics, Inc., a biotechnology company specializing in rare metabolic disease where he led the investor relations, corporate development, communications, financial planning, accounting, human resources and information technology since September 2015 after joining Aeglea as Vice President, Finance, in July 2014. Prior to joining Aeglea, Mr. York held financial management roles in the life science, pharmaceutical and technology industries and began his career at PricewaterhouseCoopers LLP. Mr. York is a CPA in the state of Arizona and received a B.S. in Accounting from the University of Connecticut and an MBA from the McCombs School of Business at the University of Texas at Austin.
- Samuel Blackman
Samuel Blackman是我们的联合创始人，自2018年11月以来一直担任我们的首席医疗官。在共同创立第一天之前，布莱克曼博士于2018年9月至2019年7月担任MavuPharma的临床开发主管，MavuPharma是一家专注于利用免疫系统治疗癌症和传染病的药物发现公司。在加入MavuPharma之前，他于2016年8月至2018年9月担任Silverback Therapeutics的临床开发主管，Silverback Therapeutics是一家开发组织靶向疗法的生物技术公司。在加入Silverback之前，Blackman博士于2014年6月至2016年8月担任专注于癌症治疗的生物技术公司Juno Therapeutics的高级医学总监，在此之前，他在Seattle Genetics，Merck和GlaxoSmithKline担任越来越重要的职务。布莱克曼博士毕业于达纳·法伯癌症研究所和波士顿儿童医院的儿科血液学/肿瘤学奖学金计划，以及辛辛那提儿童医院医疗中心的儿科住院医师计划。布莱克曼博士获得了伊利诺伊大学芝加哥分校的哲学学士学位，药理学硕士和博士学位。
Samuel Blackman is our co-founder and has served as our Chief Medical Officer since November 2018. Prior to co-founding Day One, Dr. Blackman was Head of Clinical Development at Mavupharma, a drug discovery company focused on leveraging the immune system to treat cancer and infectious diseases, from September 2018 to July 2019. Prior to Mavupharma, he was Head of Clinical Development at Silverback Therapeutics, a biotechnology company developing tissue-targeted therapeutics, from August 2016 to September 2018. Prior to Silverback, Dr. Blackman was a senior medical director at Juno Therapeutics, a biotechnology company focused on cancer treatments from June 2014 to August 2016 and before that he held roles of increasing responsibility at Seattle Genetics, Merck and GlaxoSmithKline. Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. Dr. Blackman received his B.A. in Philosophy, his M.D. and Ph.D. in Pharmacology from the University of Illinois at Chicago.- Samuel Blackman是我们的联合创始人，自2018年11月以来一直担任我们的首席医疗官。在共同创立第一天之前，布莱克曼博士于2018年9月至2019年7月担任MavuPharma的临床开发主管，MavuPharma是一家专注于利用免疫系统治疗癌症和传染病的药物发现公司。在加入MavuPharma之前，他于2016年8月至2018年9月担任Silverback Therapeutics的临床开发主管，Silverback Therapeutics是一家开发组织靶向疗法的生物技术公司。在加入Silverback之前，Blackman博士于2014年6月至2016年8月担任专注于癌症治疗的生物技术公司Juno Therapeutics的高级医学总监，在此之前，他在Seattle Genetics，Merck和GlaxoSmithKline担任越来越重要的职务。布莱克曼博士毕业于达纳·法伯癌症研究所和波士顿儿童医院的儿科血液学/肿瘤学奖学金计划，以及辛辛那提儿童医院医疗中心的儿科住院医师计划。布莱克曼博士获得了伊利诺伊大学芝加哥分校的哲学学士学位，药理学硕士和博士学位。
- Samuel Blackman is our co-founder and has served as our Chief Medical Officer since November 2018. Prior to co-founding Day One, Dr. Blackman was Head of Clinical Development at Mavupharma, a drug discovery company focused on leveraging the immune system to treat cancer and infectious diseases, from September 2018 to July 2019. Prior to Mavupharma, he was Head of Clinical Development at Silverback Therapeutics, a biotechnology company developing tissue-targeted therapeutics, from August 2016 to September 2018. Prior to Silverback, Dr. Blackman was a senior medical director at Juno Therapeutics, a biotechnology company focused on cancer treatments from June 2014 to August 2016 and before that he held roles of increasing responsibility at Seattle Genetics, Merck and GlaxoSmithKline. Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. Dr. Blackman received his B.A. in Philosophy, his M.D. and Ph.D. in Pharmacology from the University of Illinois at Chicago.